Related Experiment Video
Updated: Aug 20, 2026
Comparing Objective Conjunctival Hyperemia Grading and the Ocular Surface Disease Index Score in Dry Eye Syndrome During COVID-19
Published on: May 25, 2022
[Ocular Behçet disease. Retrospective study]
R M Torres1, B Yáñez, J M Herreras
1Unidad de Inmunología Ocular, Instituto Universitario de Oftalmobiología Aplicada, Universidad de Valladolid, Valladolid, Spain.
Objective:
To study clinical features, visual prognosis and response to immunosuppressive drugs in patients with ocular Behçet Disease (BD).
Patients And Methods:
clinical data of 17 patients (33 eyes) were retrospectively reviewed from May 1996 to May 2003.
Results:
The male/female ratio was 12/5. The commonest manifestations were oral ulceration (100%) and skin lesions (88%). Anterior uveitis was present in 59%, posterior uveitis was in 76% and panuveitis was in 88.1%. Visual acuity improved in 11 (33.3%) eyes, remind stable in 18 (54.5%) eyes and four (12.1%) eyes lost two or more lines. Main drug therapy consisted of colchicine and cyclosporine (59%). Seven patients had received three drugs simultaneously.
Conclusions:
BD can lead to an irreversible visual loss; however, the visual prognosis is good (85%) if immunosuppressor treatment is implemented.
